First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy

Nizar Tannir, Hans Hammers, Asim Amin

Research output: Contribution to journalReview article

5 Scopus citations

Abstract

Despite improved outcomes with systemic vascular endothelial growth factor (VEGF)-targeted agents in patients with advanced renal cell carcinoma (RCC), the majority of patients will eventually develop treatment resistance and disease progression. With the emergence of checkpoint inhibitors as potential treatment approaches, studies suggest that ideally combining or sequencing them with VEGF receptor (VEGFR)–tyrosine kinase inhibitors (TKIs) may provide more effective treatments that reduce or delay disease progression. Indeed, preliminary evidence suggests that VEGFR-TKIs can reverse immunosuppressive effects in the tumor microenvironment, potentially enhancing the effects of subsequent immunotherapy with checkpoint inhibitors. However, questions remain regarding the most effective treatment sequences or combinations with VEGFR-TKIs and checkpoint inhibitors. This review discusses the potential role of first-line VEGFR-TKIs in priming the tumor microenvironment for immunotherapy.

Original languageEnglish (US)
Pages (from-to)825-831
Number of pages7
JournalCurrent Medical Research and Opinion
Volume34
Issue number5
DOIs
StatePublished - May 4 2018

Keywords

  • Carcinoma
  • immunotherapy
  • pazopanib
  • renal cell
  • renal cell carcinoma
  • tyrosine kinase inhibitor
  • vascular endothelial growth factor

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy'. Together they form a unique fingerprint.

  • Cite this